-
Taxonomy & unit
-
us-gaap: shares
-
Description
-
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
-
Summary
-
Inhibitor Therapeutics, Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Diluted history and growth rate from Q2 2021 to Q3 2024.
- Inhibitor Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending September 30, 2024 was 172M shares, a 0.18% increase year-over-year.
- Inhibitor Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 172M shares, a 53% decline from 2022.
- Inhibitor Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 366M shares, a 2.68% decline from 2021.
- Inhibitor Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2021 was 376M shares.
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Growth (%)